Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS)

Posted by Stanley Muller on Aug 26th, 2026

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 10,217 put options on the stock. This represents an increase of 70% compared to the average volume of 6,015 put options.

Compass Pathways Stock Performance

NASDAQ:CMPS traded down $0.09 on Wednesday, hitting $14.79. The company’s stock had a trading volume of 597,297 shares, compared to its average volume of 3,630,745. Compass Pathways has a one year low of $4.40 and a one year high of $15.40. The firm has a market capitalization of $2.05 billion, a P/E ratio of -3.20 and a beta of 2.50. The stock has a fifty day moving average of $12.97 and a two-hundred day moving average of $9.94. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). Research analysts predict that Compass Pathways will post -1.26 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. BTIG Research increased their price objective on shares of Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Royal Bank Of Canada decreased their price target on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Morgan Stanley boosted their price target on Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Evercore raised shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price for the company in a research note on Wednesday, July 8th. Finally, Maxim Group upped their price target on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.36.

Read Our Latest Report on Compass Pathways

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CMPS. EverSource Wealth Advisors LLC boosted its holdings in shares of Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after acquiring an additional 1,920 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Compass Pathways during the 4th quarter worth approximately $38,000. Parallel Advisors LLC lifted its holdings in Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares during the last quarter. Advisory Services Network LLC bought a new stake in Compass Pathways in the 3rd quarter valued at $41,000. Finally, North Star Investment Management Corp. boosted its stake in Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after purchasing an additional 7,000 shares during the period. 46.19% of the stock is owned by institutional investors.

Compass Pathways Company Profile

(Get Free Report)

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.